India, US renew defence pact; to pursue co-production projects

January 25, 2015

modi-obama-hug-759

New Delhi, Jan 25: Vowing to take defence ties to a "new level", India and the US today renewed their 10-year Defence Framework Agreement and agreed in principle to pursue joint development and production projects.

The new framework will enhance bilateral defence partnership by stepping up joint military exercises and through more in-depth intelligence-sharing, maritime security efforts among others.

"Today, we have also decided to take our growing defence cooperation to a new level. We have agreed, in principle, to pursue co-development and co-production of specific advanced defence projects," Prime Minister Narendra Modi said after holding extensive talks with visiting US President Barack Obama here.

Modi said this will help upgrade country's domestic defence industry and expand the manufacturing sector in India.

He added that both countries will also explore cooperation in other areas of advanced defence technologies.

The Prime Minister did not specify what these projects were.

"We have renewed our Defence Framework Agreement. We will deepen our cooperation on maritime security," he said in a joint media interaction.

Obama, who arrived today on a three-day visit, welcomed the renewal of the pact and said it will guide the bilateral defence cooperation for next ten years.

"We agreed to deepen our defence and security cooperation.... And in a major step forward for our relationship, defence technology and trade initiative will allow us to jointly develop and produce defence technologies," he said.

Obama added that both Modi and he have also agreed to a "new vision for Asia Pacific".

"We are doing together more to advance our shared security and prosperity in this critical region," he said.

The first framework agreement, which expires this year, was signed in the US in 2005 by the then Defence Minister Pranab Mukherjee and his US counterpart in the previous George W.Bush administration, Donald Rumsfeld.

The most-significant aspect would be the Defence Trade and Technology Initiative (DTTI) — aimed at enhancing the ones existing under the Defence Policy Group, which lay out the path for future defence cooperation.

The US is pushing for what it calls "transformative defence technologies" for co-development and co-production with India under DTTI, which could become the hallmark of the Modi government's 'Make-in-India' initiative.

The US has offered India 17 hi-tech items of military hardware for co-production and co-development under DTTI.

Of the 17, India is understood to be interested in five, including unarmed unmanned aerial vehicles (UAVs) and aircraft landing system for aircraft carriers.

Hectic parleys were being held between the two countries on the defence front.

Frank Kendall, Under Secretary of Defence for Acquisition, Technology and Logistics (AT&L), arrived earlier this week here to hold discussions with Indian officials to come up with some "concrete" deliverables.

He is the Pentagon's point person on India-related defence issues, in particular on the India-US Defence Trade and Technology Initiative (DTTI).

His primary objective is to continue momentum on DTTI, which promotes collaboration on defence technology and enables co-production and co-development of critical defence systems.

Defence Minister Manohar Parrikar had earlier said expansion of DTTI with the US can be expected during the high-profile visit.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
January 18,2020

Shirdi, Jan 18: The administrative body of Sai Baba's Samadhi calls for the indefinite closure of the Shirdi temple after Maharashtra Chief Minister Uddhav Thackeray reportedly said Pathri in Parbhani is Sai Baba's birthplace.

"We have announced to close Shirdi against rumours from January 19," said B Wakchaure of Saibaba Sansthan Trust.

"A meeting of villagers will be convened Saturday evening to discuss the issue. Devotees will not face any difficulty if they come to Shirdi," Mr Wakchaure added.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
August 3,2020

The Drugs Controller General of India (DCGI) has given nod to the Serum Institute of India (SII) for conducting phase 2 and 3 human clinical trials of the Oxford University developed Covid-19 vaccine candidate in the country.

Government officials said that the approval for conducting phase 2 and 3 clinical trials by the SII was granted by DCGI Dr V G Somani late Sunday night after a thorough evaluation based on the recommendations of the Subject Expert Committee (SEC) on Covid-19.

"The firm has to submit safety data, evaluated by the Data Safety Monitoring Board (DSMB), to the CDSCO before proceeding to phase 3 clinical trials," a senior official said.

"As per the study design, each subject will be administered two doses four weeks apart (first dose on day one and second dose on day 29) following which the safety and immunogenicity will be assessed at predefined intervals," the official said.

As a rapid regulatory response, the expert panel at the Central Drugs Standard Control Organisation (CDSCO) on Friday, after a detailed deliberation and considering the data generated on the vaccine candidate in phase 1 and 2 of the Oxford University trial, had recommended granting permission for phase 2 and 3 clinical trials of the potential vaccine, 'Covishield', on healthy adults in India,  the officials said.

Currently, phase 2 and 3 clinical trials of the Oxford vaccine candidate is going on in the United Kingdom, phase 3 clinical trial in Brazil and phase 1 and 2 clinical trials in South Africa.

The officials said that the SII had submitted a revised proposal on Wednesday after the SEC on July 28, following deliberation over its application, had asked it to revise its protocol for the phase 2 and 3 clinical trials besides seeking some additional information.

The panel had also recommended that the clinical trial sites which have been proposed for the study be distributed across India.

According to the revised proposal by the SII, 1,600 people aged above 18 years will participate in the trials across 17 selected sites, including AIIMS-Delhi, B J Medical College in Pune, Rajendra Memorial Research Institute of Medical Sciences (RMRIMS) in Patna, Post Graduate Institute of Medical Education and Research in Chandigarh, AIIMS-Jodhpur, Nehru Hospital in Gorakhpur, Andhra Medical College in Visakhapatnam and JSS Academy of Higher Education and Research in Mysore.

"According to the application, it would conduct an observer-blind, randomised controlled study to determine the safety and immunogenicity of 'Covishield' on healthy Indian adults," the official said.

The SII, which has partnered with AstraZeneca, for manufacturing the Oxford vaccine candidate for Covid-19 had submitted its first application to the DCGI on July 25 seeking permission for conducting the phase 2 and 3 trials of the potential vaccine. 

Initial results of the first two-phases of trials of the vaccine conducted in five trial sites in the UK showed that it has an acceptable safety profile and homologous boosting increased antibody response, sources had said.

To introduce the vaccine, SII, the world's largest vaccine maker by number of doses produced and sold, has signed an agreement to manufacture the potential vaccine developed by the Jenner Institute (Oxford University) in collaboration with British-Swedish pharma company AstraZeneca. 

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 19,2020

New Delhi, Apr 19: With 1,334 fresh cases of coronavirus reported in the last 24 hours, the total number of confirmed cases of COVID-19 in India has reached 15,712 including 507 deaths, said Lav Aggarwal, Joint Secretary, Health and Family Welfare, here on Sunday.

As many as 2,231 people have recovered from the disease so far, said Aggarwal during the daily media briefing on the coronavirus. "This equals 14.1 per cent of the total cases," he added.

"A total of 15,712 confirmed cases have been reported in India including 507 deaths and 2,231 people, who were COVID-19 positive, have recovered. Out of the total deaths, 27 deaths have been reported in the last 24 hours," said Aggarwal.

The Joint Secretary said that no new case was reported in Mahe in Puducherry and Karnataka's Kodagu in the last 28 days.

"A total of 54 other districts beside these two in 23 States/Union Territories did not report any cases in the last 14 days," he said.

He informed that there are 755 dedicated COVID-19 hospitals and 1,389 dedicated health care centres in the country, which takes the total dedicated facilities where severe or critical patients can be treated to 2,144.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.